Markets

What's behind GSK's massive earnings and will the stock price surge continue?

Over the past 12 months, Pakistan’s pharmaceutical sector has delivered stellar stock performance

avatar-icon

Shahbaz Ashraf

Business Consultant

Seasoned Investment Professional | CFA | 17+ Years of Experience in Equity Research, Valuation & Advisory Seasoned investment professional with over 17 years of experience in equity research, financial analysis, valuations, and investment advisory—primarily focused on financial services firms, including equity brokerages, asset management companies, and family offices. Skilled in financial modeling, portfolio management, and evaluating multi-asset investment opportunities. Known for delivering data-driven insights and actionable strategies tailored to both institutional and private clients. Holds a BBA and MBA in Finance from the Institute of Business Management (IoBM), Karachi, and is a Chartered Financial Analyst (CFA).

Full Bio
What's behind GSK's massive earnings and will the stock price surge continue?play icon
- YouTube

youtu.be

Over the past 12 months, Pakistan’s pharmaceutical sector has delivered stellar stock performance, driven by long-overdue regulatory relief, including significant price hikes in 2023–2024.

This shift came after years of capped prices, surging API costs, and currency depreciation that had severely squeezed margins.

GSK Pakistan, in particular, posted dramatic earnings rebound — from PKR 534 million in 2023 to over PKR 6.5 billion in 2024 — led by improved pricing and margin expansion.

Watch the full video for a comprehensive pharma industry analysis and stock analysis of GSK.

Comments

See what people are discussing

Back To Top